AR052322A1 - Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica - Google Patents

Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica

Info

Publication number
AR052322A1
AR052322A1 ARP050104637A ARP050104637A AR052322A1 AR 052322 A1 AR052322 A1 AR 052322A1 AR P050104637 A ARP050104637 A AR P050104637A AR P050104637 A ARP050104637 A AR P050104637A AR 052322 A1 AR052322 A1 AR 052322A1
Authority
AR
Argentina
Prior art keywords
preparation
processes
estaurosporine
benzoil
compounds
Prior art date
Application number
ARP050104637A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052322(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR052322A1 publication Critical patent/AR052322A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP050104637A 2004-11-05 2005-11-04 Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica AR052322A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07

Publications (1)

Publication Number Publication Date
AR052322A1 true AR052322A1 (es) 2007-03-14

Family

ID=35501294

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104637A AR052322A1 (es) 2004-11-05 2005-11-04 Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica

Country Status (31)

Country Link
US (2) US8198435B2 (enExample)
EP (3) EP1812448B1 (enExample)
JP (4) JP5057986B2 (enExample)
KR (3) KR101333851B1 (enExample)
CN (2) CN102993213A (enExample)
AR (1) AR052322A1 (enExample)
AU (2) AU2005300693B2 (enExample)
BR (1) BRPI0517689A (enExample)
CA (1) CA2584911C (enExample)
CY (1) CY1113059T1 (enExample)
DK (1) DK1812448T3 (enExample)
EC (1) ECSP12007431A (enExample)
ES (1) ES2388142T3 (enExample)
GT (1) GT200500311A (enExample)
HK (1) HK1211587A1 (enExample)
HR (1) HRP20120652T1 (enExample)
IL (3) IL182691A (enExample)
JO (1) JO2897B1 (enExample)
MA (1) MA29033B1 (enExample)
MX (2) MX346525B (enExample)
MY (2) MY147404A (enExample)
NO (2) NO338960B1 (enExample)
NZ (3) NZ599033A (enExample)
PE (3) PE20130377A1 (enExample)
PL (1) PL1812448T3 (enExample)
PT (1) PT1812448E (enExample)
RU (2) RU2394038C2 (enExample)
SI (1) SI1812448T1 (enExample)
TN (1) TNSN07165A1 (enExample)
TW (4) TWI530500B (enExample)
WO (1) WO2006048296A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
EP3592749A1 (en) * 2017-03-06 2020-01-15 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
US20220242880A1 (en) * 2019-06-24 2022-08-04 Dr. Reddy?s Laboratories Limited Process for preparation of midostaurin
IT201900014346A1 (it) * 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2023205504A1 (en) * 2022-04-22 2023-10-26 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
US5344926A (en) 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
RU2191175C2 (ru) * 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
BR9917475B1 (pt) * 1999-08-30 2013-07-23 processo para a manufatura de compostos, e, modificação do processo.
CA2439097C (en) 2001-03-26 2010-10-12 Novartis Ag Pharmaceutical compositions
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
WO2004094645A1 (en) * 2003-04-22 2004-11-04 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Also Published As

Publication number Publication date
RU2467012C2 (ru) 2012-11-20
TW201247680A (en) 2012-12-01
PL1812448T3 (pl) 2012-10-31
GT200500311A (es) 2006-05-22
JP2012149099A (ja) 2012-08-09
IL207702A0 (en) 2010-12-30
JP5701246B2 (ja) 2015-04-15
TNSN07165A1 (en) 2008-11-21
US8198435B2 (en) 2012-06-12
PE20130377A1 (es) 2013-04-03
IL182691A0 (en) 2007-09-20
PE20090433A1 (es) 2009-05-05
US20090137552A1 (en) 2009-05-28
JP2008518995A (ja) 2008-06-05
RU2009137788A (ru) 2011-04-20
TWI530501B (zh) 2016-04-21
MY147404A (en) 2012-11-30
TWI530500B (zh) 2016-04-21
RU2007120695A (ru) 2008-12-10
EP2955186A1 (en) 2015-12-16
WO2006048296A1 (en) 2006-05-11
NO340404B1 (no) 2017-04-18
MY154878A (en) 2015-08-14
MX346525B (es) 2017-03-23
PT1812448E (pt) 2012-08-24
EP2272850A3 (en) 2011-09-21
AU2009245817A1 (en) 2009-12-24
BRPI0517689A (pt) 2008-10-14
US8710216B2 (en) 2014-04-29
JP2015063569A (ja) 2015-04-09
EP1812448B1 (en) 2012-05-23
TWI433852B (zh) 2014-04-11
NO20072290L (no) 2007-05-30
HRP20120652T1 (hr) 2012-09-30
EP1812448A1 (en) 2007-08-01
NO20161152A1 (no) 2007-05-30
US20120322789A1 (en) 2012-12-20
IL217571A (en) 2017-07-31
PE20060947A1 (es) 2006-10-30
JP2017061578A (ja) 2017-03-30
KR20070083979A (ko) 2007-08-24
KR101289998B1 (ko) 2013-07-30
CN102993213A (zh) 2013-03-27
AU2005300693B2 (en) 2010-08-19
NO338960B1 (no) 2016-11-07
HK1211587A1 (en) 2016-05-27
SI1812448T1 (sl) 2012-09-28
TW200628474A (en) 2006-08-16
JO2897B1 (en) 2015-09-15
TW201446773A (zh) 2014-12-16
AU2005300693A1 (en) 2006-05-11
MA29033B1 (fr) 2007-11-01
EP2272850A2 (en) 2011-01-12
NZ599033A (en) 2012-09-28
DK1812448T3 (da) 2012-08-27
NZ588025A (en) 2012-04-27
KR101333851B1 (ko) 2013-11-27
IL182691A (en) 2013-02-28
ECSP12007431A (es) 2012-06-29
TW201247681A (en) 2012-12-01
TWI455941B (zh) 2014-10-11
KR20120101600A (ko) 2012-09-13
CN102627658A (zh) 2012-08-08
AU2009245817B2 (en) 2013-02-21
CA2584911A1 (en) 2006-05-11
KR101265850B1 (ko) 2013-05-20
EP2272850B1 (en) 2017-05-10
JP5057986B2 (ja) 2012-10-24
HK1108881A1 (en) 2008-05-23
CY1113059T1 (el) 2016-04-13
CA2584911C (en) 2017-10-24
KR20120101601A (ko) 2012-09-13
RU2394038C2 (ru) 2010-07-10
NZ554653A (en) 2010-10-29
MX2007005429A (es) 2007-05-18
ES2388142T3 (es) 2012-10-09
IL207702A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
ECSP12007431A (es) Compuestos orgánicos
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
AR063923A1 (es) Sales del acido zoledronico, procesos de preparacion y composiciones
SV2009002832A (es) 1h imidazopiridinas sustituidas con hidroxi y procedimientos
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
CR9987A (es) Compuestos de lactama y métodos de uso de los mismos
UY32302A (es) Carboxamidas heterobicíclicas como inhibidoras de cinasas
CL2008001373A1 (es) Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer.
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
CR9672A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores
AR047928A1 (es) Derivados de tetrahidropiridoindol
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
CL2008001721A1 (es) Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
CL2011002130A1 (es) Uso de una composicion que comprende una mezcla fisica o combinacion de polvos, granulos, cristales o agregados de sales de calcio, magnecio y hierro para el tratamiento de enfermedades relacionadas con la absorcion alterada de fosforo en seres humanos y animales.
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
BR112012022243A8 (pt) Uso de um inibidor de autofagia baseado em tioxantona e de um composto indutor de autofagia para terapia de câncer, composição farmacêutica e kit farmacêutico
AR077138A1 (es) Composiciones farmaceuticas utiles para tratar el vhc
ECSP055575A (es) Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.

Legal Events

Date Code Title Description
FC Refusal